Adiponectin has consistently shown a negative association with BMD, however, targeting low levels of adiponectin is debatable as it serves as a protective biomarker for other metabolic conditions such as insulin resistance and diabetes. This evidence concerns the gene ADIPOQ and Insulin resistance.